** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 2% to $62.70
** Co says the U.S. FDA has given expanded approval for Iluvien to treat chronic, non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)
** NIU-PS is characterized by inflammation of the retina or optic nerve of the eye
** Iluvien is already approved by the FDA to treat another eye condition called diabetic macular edema $(DME.AU)$
** Co plans to market Iluvien under the combined label in the U.S. later this year
** Up to last close, ANIP has fallen 7.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。